Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF
(World News USA)

Data demonstrates MANF`s role in modulating the immune microenvironment in the retina and its potential for treating retinal disorders Patent extends MANF Therapeutics` exclusivity for MANF and CDNF treatment of retinal disorders in Japan into 2031 SAN FRANCISCO, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced the publication of positive pre-clinical data for mesencephalic astrocyte-derived neurotrophic factor (MANF) in the treatment of retinal damage in the prestigious...